Keryx Biopharmaceuticals, Inc. to Present at The Bear Stearns 16th Annual 
                            Healthcare Conference 
 
    NEW YORK, Sept. 5 -- Keryx Biopharmaceuticals, Inc. 
(Nasdaq: KERX; AIM: KRX), a biopharmaceutical company focused on the 
acquisition, development and commercialization of novel pharmaceutical 
products for the treatment of life-threatening diseases, including diabetes 
and cancer, announced today that Michael S. Weiss, Chairman and Chief 
Executive Officer, will present an overview of the Company's strategic plans 
and recent developments at the Bear Stearns 16th Annual Healthcare Conference 
in New York City. Mr. Weiss's presentation will take place on Monday, 
September 8, 2003, at 2:00 pm EST, in the Le Louvre Room, located on the 1st 
floor of the Plaza Hotel.   A live audio webcast and a 60-day audio archive of 
the presentation will be available via the following link:  
    http://customer.nvglb.com/BEAR002/090803a_cy/default.asp?entity=keryx 
 
    About Keryx Biopharmaceuticals, Inc.  
    Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a 
biopharmaceuticals company focused on the acquisition, development and 
commercialization of novel pharmaceutical products for the treatment of  
life-threatening diseases, including diabetes and cancer. Keryx is developing 
KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound, for the 
treatment of diabetic nephropathy, for which Keryx is currently planning its 
U.S.-based Phase II/III clinical program. Keryx also has an active  
in-licensing program designed to identify and acquire clinical-stage drug 
candidates. Additionally, Keryx is seeking partners for its KinAce(TM) drug 
discovery technology and related products. Keryx Biopharmaceuticals is 
headquartered in New York City.  
 
    Contact: 
     Ron Bentsur               
     VP Finance and Investor Relations   
     Keryx Biopharmaceuticals, Inc.           
     Tel: +1-212-531-5965           
     E-mail: ron@keryx.com 
 
SOURCE  Keryx Biopharmaceuticals, Inc. 
    -0-                             09/05/2003 
    /CONTACT:  Ron Bentsur, VP Finance and Investor Relations of Keryx 
Biopharmaceuticals, Inc., +1-212-531-5965, or ron@keryx.com / 
    (KERX) 





END